Please assess the completion status of the following clinical trial:

Trial Title: A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veteran~* age 18-70~* a diagnosis of schizophrenia, schizophreniform, schizoaffective, or brief psychotic disorder determined by the Structured Clinical Interview for DSM-5~* no medication changes or psychiatric hospitalizations in the past month~* SFS modified raw score of no more than 75~Exclusion Criteria:~* substance use disorder in the past month, except mild to moderate cannabis use disorder~* illness affecting the nasal passages~* significant neurological/medical disorder~* pacemakers~* extensive dental work~* claustrophobia~* deafness~* inability to read~* currently participating in a psychosocial intervention targeting social functioning deficits~* currently taking high dose testosterone or estrogen/progesterone~* inability to complete VOT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal Oxytocin (Type: EXPERIMENTAL): Dosages of oxytocin: 20IU or 40IU.
- Placebo (Type: PLACEBO_COMPARATOR): Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).